Advertisement
Advertisement
U.S. markets open in 2 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Inovio Pharmaceuticals Inc (GBMB.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
1.5348+0.0444 (+2.98%)
As of 12:01PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1.4904
Open1.5242
Bid1.5328 x N/A
Ask1.5898 x N/A
Day's Range1.5160 - 1.5348
52 Week Range1.2960 - 3.5925
Volume17
Avg. Volume8
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GBMB.DU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • American City Business Journals

      Inovio Pharmaceuticals enacts its second round of layoffs in just over six months

      The company also announced court approval of a previously disclosed $44 million settlement to resolve a class-action shareholder lawsuit.

    • Benzinga

      INOVIO Announces Further Reorganization, Continues Focus on Promising DNA Candidates

      INOVIO Pharmaceuticals (NASDAQ: INO) announced a strategic reorganization expected to provide annual savings of approximately $4.3 million and includes an 11% reduction of full-time employees following the previously announced discontinuation of clinical development programs in late 2022. In October, the company discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. These and other strategic measures redirect resources to advance key programs,

    • PR Newswire

      INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

      INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of DNA medicines to patients. The reorganization is expected to provide annual savings of approximately $4.3 million and includes an 11% r

    Advertisement
    Advertisement